Relmada Therapeutics – Consensus Indicates Potential 91.1% Upside

Broker Ratings

Relmada Therapeutics with ticker code (RLMD) now have 6 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 75 and 38 calculating the mean target price we have 62.83. Now with the previous closing price of 32.87 this would imply there is a potential upside of 91.1%. The day 50 moving average is 34.12 and the 200 moving average now moves to 38.03. The company has a market cap of $534m. Company Website:

The potential market cap would be $1,021m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Relmada Therapeutics, a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of depression, neuropathic pain, and other potential CNS pathological conditions. The company is also developing LevoCap ER, an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; BuTab, an oral dosage form of the opioid analgesic buprenorphine; and MepiGel, an orphan drug designated topical formulation of the local anesthetic mepivacaine. Relmada Therapeutics was founded in 2004 and is headquartered in New York, New York.

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index